In Silico Study of Indole–Tetrazole Hybrid Derivatives as Potential Breast Cancer Anticancer Candidates Through Molecular Docking Against HER2, ADMET Profile Prediction, and Drug-Likeness Assessment
DOI:
10.29303/jpm.v21i5.11980Published:
2026-10-29Downloads
Abstract
Breast cancer remains one of the leading causes of mortality among women worldwide, highlighting the urgent need for the development of more effective therapeutic agents with fewer adverse effects. This study aimed to analyze the potential of indole–tetrazole hybrid derivatives as anti-breast cancer agents by comparing their performance with the reference compound Bazedoxifen. The design of indole–tetrazole hybrid compounds, which integrates two pharmacologically active moieties within a single molecular framework, is expected to enhance biological activity and strengthen interactions with target proteins. The methods employed in this study included molecular docking to evaluate ligand binding affinity to the HER2 protein (PDB ID: 7PCD), Lipinski’s Rule of Five analysis to assess drug-likeness for oral administration, and ADMET prediction to evaluate pharmacokinetic and toxicity profiles. SwissADME and pkCSM were used to assess the drug-likeness of the compounds based on Lipinski’s Rule of Five and to predict their ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. The key parameters analyzed in the docking study were binding affinity (ΔG), root mean square deviation (RMSD), and the types of interactions with amino acid residues at the active site. The results indicated that most compounds satisfied Lipinski’s criteria and exhibited good absorption profiles, as well as non-mutagenic properties based on Ames test predictions. Compound 10 exhibited the best binding affinity (−13.0444 kcal/mol) and showed interactions with key amino acid residues, indicating a stable ligand–protein complex. Overall, compound 10 was identified as the most promising candidate for further development as an anti-breast cancer agent. However, further experimental validation through both in vitro and in vivo studies is required to confirm the compound's pharmacological potential and safety profile before it can be considered for drug development.
Keywords:
ADMET Breast Cancer Drug-Likeness Assessment Indole–tetrazole Molecular DockingReferences
[1] S. Bajaj, P. P. Roy, and J. Singh, “Synthesis, thymidine phosphorylase inhibitory and computational study of novel 1,3,4-oxadiazole-2-thione derivatives as potential anticancer agents,” Comput. Biol. Chem., vol. 76, pp. 151–160, 2018, doi: 10.1016/j.compbiolchem.2018.05.013.
[2] B. S. Lakshmi, J. K. Bidarur, H. G. Anilkumar, and B. S. Ravindranath, “Prioritization of phytochemical isolation and characterization against HER2 as a breast cancer target based on chromatographic methods , DFT,” vol. 2, pp. 25103–25114, 2025, doi: 10.1039/d5ra01800e.
[3] E. D. O. Sihite, S. Nurchayati, and Y. Hasneli, “Gambaran Tingkat Pengetahuan Tentang Kanker Payudara Dan Perilaku Periksa Payudara Sendiri (Sadari),” J. Ners Indones., vol. 9, no. 2, p. 8, 2019, doi: 10.31258/jni.10.1.8-20.
[4] D. Qian et al., “Trends in the global , national , and regional burden of breast cancer among adolescents and young adults from 1990 to 2021 : Analyses of the 2021 global burden of disease study,” The Breast, vol. 82, no. May, p. 104486, 2025, doi: 10.1016/j.breast.2025.104486.
[5] J. P. Arisanti, N. Saptarina, and Y. D. Andarini, “Evaluasi Penggunaan Obat Kemoterapi Pada Penderita Kanker Payudara Di Rsup Dr. Seoradji Tirtonegoro Periode 2018,” Pharm. J. Islam. Pharm., vol. 4, no. 2, p. 1, 2020, doi: 10.21111/pharmasipha.v4i2.4960.
[6] I. Nurjayanti, “DUKUNGAN KELUARGA PADA PASIEN KANKER PAYUDARA DENGAN KEMOTERAPI DI RUMAH SAKIT PKU MUHAMMADIYAH YOGYAKARTA,” vol. 17, no. 1, pp. 1–23, 2019.
[7] M. Nilashi, H. Ahmadi, R. Ali, M. Alrizq, A. Alghamdi, and S. Alyami, “Heliyon Knowledge discovery of patients reviews on breast cancer drugs : Segmentation of side effects using machine learning techniques,” Heliyon, vol. 10, no. 19, p. e38563, 2024, doi: 10.1016/j.heliyon.2024.e38563.
[8] Ruswanto, “DESAIN DAN STUDI IN-SILICO TURUNAN TIOUREA SEBAGAI KANDIDAT RADIOFARMAKA 131I-THIOUREA UNTUK KANKER PAYUDARA,” vol. 8, no. 1, pp. 133–150, 2025.
[9] E. Rubin et al., “Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 ( HER2 ) Genes across Various Cancers,” vol. 2, 2024.
[10] Y. M. Panji Bachrudin, Agus Sulaeman, “PENDEKATAN TERAPI MOLEKULER PADA KANKER PAYUDARA TERHADAP PERAN EVEROLIMUS DAN TEMSIROLIMUS SEBAGAI PROTEIN KINASE INHIBITORS JALUR PI3K/AKT/MTOR,” vol. 8, no. 1, pp. 179–191, 2025, doi: 10.36387/jifi.v8i1.2508.
[11] M. Arumí, M. Bellet, and C. Saura, “HER2-positive breast cancer : Current and new therapeutic strategies,” vol. 39, pp. 80–88, 2018, doi: 10.1016/j.breast.2018.03.006.
[12] H. Rahma et al., “Peran Human Epidermal Growth Factor Receptor-2 pada Kanker Payudara Role of Human Epidermal Growth Factor Receptor-2 in Breast Cancer,” vol. 5, pp. 644–647, 2018.
[13] X. Cheng, “A Comprehensive Review of HER2 in Cancer Biology and Therapeutics,” 2024.
[14] G. S. P. Matada et al., “Pharmacophore modeling, virtual screening, molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: An in-silico approach,” J. Mol. Struct., vol. 1257, p. 132531, 2022, doi: 10.1016/j.molstruc.2022.132531.
[15] R. K. Amewu, P. O. Sakyi, and D. Osei-safo, Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets. 2021.
[16] T. T. Y. Wang, M. J. Milner, J. A. Milner, and Y. S. Kim, “Estrogen receptor a as a target for indole-3-carbinol,” pp. 3–8, 2006, doi: 10.1016/j.jnutbio.2005.10.012.
[17] A. Elkamhawy et al., “Scaffold repurposing of in-house small molecule candidates leads to discovery of first-in-class cdk-1/her-2 dual inhibitors: In vitro and in silico screening,” Molecules, vol. 26, no. 17, pp. 1–12, 2021, doi: 10.3390/molecules26175324.
[18] F. Islam et al., “Indole alkaloids from marine resources: Understandings from therapeutic point of view to treat cancers,” Chem. Biol. Interact., vol. 383, no. July, p. 110682, 2023, doi: 10.1016/j.cbi.2023.110682.
[19] N. Dhiman, K. Kaur, and V. Jaitak, “Bioorganic & Medicinal Chemistry Tetrazoles as anticancer agents : A review on synthetic strategies , mechanism of action and SAR studies,” Bioorg. Med. Chem., vol. 28, no. 15, p. 115599, 2020, doi: 10.1016/j.bmc.2020.115599.
[20] K. Kaur, H. Verma, P. Gangwar, M. Dhiman, and V. Jaitak, “Design, synthesis, in vitro and in silico evaluation of indole-based tetrazole derivatives as putative anti-breast cancer agents,” RSC Med. Chem., vol. 15, pp. 1329–1347, 2024, doi: 10.1039/D3MD00730H.
[21] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings,” Adv. Drug Deliv. Rev., vol. 64, no. SUPPL., pp. 4–17, 2012, doi: 10.1016/j.addr.2012.09.019.
[22] L. Blanca, R. Estrada-tejedor, and E. a. Borrell, Jos I, “Evaluation of Free Online ADMET Tools for Academic or Small Biotech Environments,” 2023.
[23] R. Roskoski, “Rule of five violations among the FDA-approved small molecule protein kinase inhibitors,” Pharmacol. Res., vol. 191, no. April, p. 106774, 2023, doi: 10.1016/j.phrs.2023.106774.
[24] G. Sampat, S. S. Suryawanshi, M. S. Palled, and A. S. Patil, “Drug Likeness Screening and Evaluation of Physicochemical Properties of Selected Medicinal Agents by Computer Aided Drug Design Tools,” vol. 10, no. 4, pp. 234–246, 2022, doi: 10.13189/app.2022.100402.
[25] R. Feghali, R. P. Ribeiro, M. J. Ramos, and P. A. Fernandes, “The importance of intramolecular hydrogen bonds on the translocation of the small drug piracetam through a lipid bilayer †,” pp. 899–908, 2021, doi: 10.1039/d0ra09995c.
[26] O. Nursanti, “Validasi Penambatan Molekul Untuk Mendapatkan Ligan Aktif Pada Reseptor Cyclooxygenase 2,” Pros. Semin. Inf. Kesehat. Nas., pp. 411–430, 2019.
[27] S. D. Lina Elfita, Anjas Apriadi, Supandi, “Studi Penambatan Molekuler dan Simulasi Dinamika Molekuler Senyawa Turunan Furanokumarin terhadap Reseptor Estrogen Alfa ( ER-α ) Sebagai Anti Kanker Payudara,” pp. 255–264, 2022, doi: 10.25077/jsfk.9.3.255-264.2022.
[28] R. Zainul et al., “In Silico Gene Transcription of 4-Hydroxycinnamic Acid from Broccoli Fruit ( Brassica oleracea var . italica ) with Estrogen Receptor Beta Protein,” vol. 16, no. 4, pp. 791–796, 2024.
[29] D. Ramirez and J. Caballero, “Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data ?,” pp. 1–17, 2018, doi: 10.3390/molecules23051038.
[30] D. T. Truong et al., “Benchmarking the Ligand − HER2 Interactions Using Machine Learning and Molecular Dynamics Simulations,” 2026, doi: 10.1021/acsomega.5c10459.
[31] Zoete, “Docking, virtual high throughput screening and in silico fragment-based drug design,” J. Cell. Mol. Med., vol. 13, no. 2, pp. 238–248, 2009, doi: 10.1111/j.1582-4934.2008.00665.x.
[32] Y. Mei et al., “Letters in Drug Design & Discovery Mechanism of Yangxuetongmai Decoction in treating essential hypotension : A network pharmacology , Mendelian randomization and molecular docking strategy analysis,” Lett. Drug Des. Discov., no. February, p. 100008, 2025, doi: 10.1016/j.lddd.2025.100008.
[33] A. Grosdidier, “EADock: Docking of Small Molecules Into Protein Active Sites With a Multiobjective Evolutionary Optimization,” El Sist. argentino innovación Inst. Empres. y redes. El desafío la creación y apropiación Conoc., vol. 14, no. October 2006, pp. 659–664, 2013, doi: 10.1002/prot.
[34] W. Ouyang, C. Zhu, Y. Li, H. Huang, F. Li, and L. Ling, “Assessing the neurotoxic risks of triethyl citrate in daily environmental exposure using network toxicology and molecular docking,” Ecotoxicol. Environ. Saf., vol. 297, no. March, p. 118225, 2025, doi: 10.1016/j.ecoenv.2025.118225.
[35] N. Forouzesh and N. Mishra, “An Effective MM / GBSA Protocol for Absolute Binding Free,” 2021.
License
Copyright (c) 2026 Zafrinaldi Zafrinaldi, Fajriah Azra
This work is licensed under a Creative Commons Attribution 4.0 International License.
The following terms apply to authors who publish in this journal:
1. Authors retain copyright and grant the journal first publication rights, with the work simultaneously licensed under a Creative Commons Attribution License 4.0 International License (CC-BY License) that allows others to share the work with an acknowledgment of the work's authorship and first publication in this journal.
2. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., posting it to an institutional repository or publishing it in a book), acknowledging its initial publication in this journal.
3. Before and during the submission process, authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website), as this can lead to productive exchanges as well as earlier and greater citation of published work (See The Effect of Open Access).
Downloads
How to Cite
